Surrogate anti-murine CD19 CAR T cells in lymphodepleted syngeneic CD19+ B-cell lymphoma mice
“Additionally, an in vivo study conducted using an analogous murine CAR construct recognizing the murine CD19 molecule demonstrated anti-tumor activity and increased survival in a lymphodepleted syngeneic adoptive transfer mouse model of CD19+ B cell lymphoma.”
✓ VerifiedFDA summary basis for approval, p. 11Source ↗
Why that model
FMC63 scFv recognises only human CD19, so a murine surrogate CAR was engineered for immunocompetent mice
“Since the anti-CD19 scFv utilised for KTE-X19 does only recognise human CD19, a murine surrogate model was engineered for non-clinical proof-of-concept studies in immune competent mice.”
EMA: surrogate model acceptable with clear limitations; xenograft testing of KTE-X19 would add no significant value
“Since both models do have clear, although differing, limitations with regard to the translation of the non-clinical pharmacology data to human, additional non-clinical in vivo pharmacology data (e.g. testing of KTE-X19 in immunocompromised animals transplanted with human CD19+ tumour cells) would not add significant value to the available non-clinical and clinical pharmacology data sets.”
autologous cultured chondrocytes on porcine collagen membrane · Autologous chondrocytes
Analogous MACI (animal cells on same membrane) in critical-sized knee/stifle cartilage defects in rabbits and horses: improved repair vs membrane alone or empty defect